APO Research
Talk to an analyst

APO RESEARCH · REPORT

Granulomatosis with Polyangiitis Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Granulomatosis with Polyangiitis Drug Market Outlook and Growth Opportunities 2026

26 December 2025190 pages

Choose your research edition.

Industry ResearchGranulomatosis with Polyangiitis Drug Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Granulomatosis with Polyangiitis Drug Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Granulomatosis with Polyangiitis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Granulomatosis with Polyangiitis Drug Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Granulomatosis with Polyangiitis Drug Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Granulomatosis with Polyangiitis Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Granulomatosis with Polyangiitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Granulomatosis with Polyangiitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Granulomatosis with Polyangiitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Granulomatosis with Polyangiitis Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Granulomatosis with Polyangiitis Drug market include Sandoz International GmbH, GlaxoSmithKline Plc, The International Biotechnology Center (IBC) Generium, Panacea Biotec Ltd, Iltoo Pharma, Genor BioPharma Co Ltd, Coherus BioSciences Inc, ChemoCentryx Inc and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Granulomatosis with Polyangiitis Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Granulomatosis with Polyangiitis Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Granulomatosis with Polyangiitis Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Granulomatosis with Polyangiitis Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Granulomatosis with Polyangiitis Drug Segment by Company

Sandoz International GmbH

GlaxoSmithKline Plc

The International Biotechnology Center (IBC) Generium

Panacea Biotec Ltd

Iltoo Pharma

Genor BioPharma Co Ltd

Coherus BioSciences Inc

ChemoCentryx Inc

Bristol-Myers Squibb Company

Bionovis SA

Granulomatosis with Polyangiitis Drug Segment by Type

Avacopan

Benralizumab

Rituximab Biosimilar

Others

Granulomatosis with Polyangiitis Drug Segment by Application

Hospital

Clinic

Others

Granulomatosis with Polyangiitis Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Granulomatosis with Polyangiitis Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Granulomatosis with Polyangiitis Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Granulomatosis with Polyangiitis Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Granulomatosis with Polyangiitis Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Granulomatosis with Polyangiitis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Granulomatosis with Polyangiitis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Granulomatosis with Polyangiitis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Granulomatosis with Polyangiitis Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Granulomatosis with Polyangiitis Drug industry.

Chapter 3: Detailed analysis of Granulomatosis with Polyangiitis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Granulomatosis with Polyangiitis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Granulomatosis with Polyangiitis Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Granulomatosis with Polyangiitis Drug Industry Trends Table 2. Granulomatosis with Polyangiitis Drug Industry Drivers Table 3. Granulomatosis with Polyangiitis Drug Industry Opportunities and Challenges Table 4. Granulomatosis with Polyangiitis Drug Industry Restraints Table 5. Global Granulomatosis with Polyangiitis Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Granulomatosis with Polyangiitis Drug Revenue Share by Company (2021-2026) Table 7. Global Granulomatosis with Polyangiitis Drug Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Granulomatosis with Polyangiitis Drug Sales Volume Share by Company (2021-2026) Table 9. Global Granulomatosis with Polyangiitis Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Granulomatosis with Polyangiitis Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Granulomatosis with Polyangiitis Drug Key Company Manufacturing Base & Headquarters Table 12. Global Granulomatosis with Polyangiitis Drug Company, Product Type & Application Table 13. Global Granulomatosis with Polyangiitis Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Granulomatosis with Polyangiitis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Avacopan Table 18. Significant Companies of Benralizumab Table 19. Significant Companies of Rituximab Biosimilar Table 20. Significant Companies of Others Table 21. Global Granulomatosis with Polyangiitis Drug Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 22. Global Granulomatosis with Polyangiitis Drug Sales Volume by Type (2021-2026) & (W Units) Table 23. Global Granulomatosis with Polyangiitis Drug Sales Volume by Type (2027-2032) & (W Units) Table 24. Global Granulomatosis with Polyangiitis Drug Sales Volume Share by Type (2021-2026) Table 25. Global Granulomatosis with Polyangiitis Drug Sales Volume Share by Type (2027-2032) Table 26. Global Granulomatosis with Polyangiitis Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Granulomatosis with Polyangiitis Drug Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Granulomatosis with Polyangiitis Drug Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Granulomatosis with Polyangiitis Drug Sales Value Share by Type (2021-2026) Table 30. Global Granulomatosis with Polyangiitis Drug Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Clinic Table 33. Significant Companies of Others Table 34. Global Granulomatosis with Polyangiitis Drug Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 35. Global Granulomatosis with Polyangiitis Drug Sales Volume by Application (2021-2026) & (W Units) Table 36. Global Granulomatosis with Polyangiitis Drug Sales Volume by Application (2027-2032) & (W Units) Table 37. Global Granulomatosis with Polyangiitis Drug Sales Volume Share by Application (2021-2026) Table 38. Global Granulomatosis with Polyangiitis Drug Sales Volume Share by Application (2027-2032) Table 39. Global Granulomatosis with Polyangiitis Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Granulomatosis with Polyangiitis Drug Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Granulomatosis with Polyangiitis Drug Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Granulomatosis with Polyangiitis Drug Sales Value Share by Application (2021-2026) Table 43. Global Granulomatosis with Polyangiitis Drug Sales Value Share by Application (2027-2032) Table 44. Global Granulomatosis with Polyangiitis Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 45. Global Granulomatosis with Polyangiitis Drug Sales by Region (2021-2026) & (W Units) Table 46. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2021-2026) Table 47. Global Granulomatosis with Polyangiitis Drug Sales by Region (2027-2032) & (W Units) Table 48. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2027-2032) Table 49. Global Granulomatosis with Polyangiitis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Granulomatosis with Polyangiitis Drug Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Granulomatosis with Polyangiitis Drug Sales Value Share by Region (2021-2026) Table 52. Global Granulomatosis with Polyangiitis Drug Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Granulomatosis with Polyangiitis Drug Sales Value Share by Region (2027-2032) Table 54. Global Granulomatosis with Polyangiitis Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Granulomatosis with Polyangiitis Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Granulomatosis with Polyangiitis Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. Global Granulomatosis with Polyangiitis Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Granulomatosis with Polyangiitis Drug Sales by Country (2021-2026) & (W Units) Table 59. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2021-2026) Table 60. Global Granulomatosis with Polyangiitis Drug Sales by Country (2027-2032) & (W Units) Table 61. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2027-2032) Table 62. Global Granulomatosis with Polyangiitis Drug Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Granulomatosis with Polyangiitis Drug Sales Value Market Share by Country (2021-2026) Table 64. Global Granulomatosis with Polyangiitis Drug Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Granulomatosis with Polyangiitis Drug Sales Value Market Share by Country (2027-2032) Table 66. Sandoz International GmbH Company Information Table 67. Sandoz International GmbH Business Overview Table 68. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product Portfolio Table 70. Sandoz International GmbH Recent Development Table 71. GlaxoSmithKline Plc Company Information Table 72. GlaxoSmithKline Plc Business Overview Table 73. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product Portfolio Table 75. GlaxoSmithKline Plc Recent Development Table 76. The International Biotechnology Center (IBC) Generium Company Information Table 77. The International Biotechnology Center (IBC) Generium Business Overview Table 78. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product Portfolio Table 80. The International Biotechnology Center (IBC) Generium Recent Development Table 81. Panacea Biotec Ltd Company Information Table 82. Panacea Biotec Ltd Business Overview Table 83. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product Portfolio Table 85. Panacea Biotec Ltd Recent Development Table 86. Iltoo Pharma Company Information Table 87. Iltoo Pharma Business Overview Table 88. Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Iltoo Pharma Granulomatosis with Polyangiitis Drug Product Portfolio Table 90. Iltoo Pharma Recent Development Table 91. Genor BioPharma Co Ltd Company Information Table 92. Genor BioPharma Co Ltd Business Overview Table 93. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product Portfolio Table 95. Genor BioPharma Co Ltd Recent Development Table 96. Coherus BioSciences Inc Company Information Table 97. Coherus BioSciences Inc Business Overview Table 98. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product Portfolio Table 100. Coherus BioSciences Inc Recent Development Table 101. ChemoCentryx Inc Company Information Table 102. ChemoCentryx Inc Business Overview Table 103. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product Portfolio Table 105. ChemoCentryx Inc Recent Development Table 106. Bristol-Myers Squibb Company Company Information Table 107. Bristol-Myers Squibb Company Business Overview Table 108. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product Portfolio Table 110. Bristol-Myers Squibb Company Recent Development Table 111. Bionovis SA Company Information Table 112. Bionovis SA Business Overview Table 113. Bionovis SA Granulomatosis with Polyangiitis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Bionovis SA Granulomatosis with Polyangiitis Drug Product Portfolio Table 115. Bionovis SA Recent Development Table 116. Key Raw Materials Table 117. Raw Materials Key Suppliers Table 118. Granulomatosis with Polyangiitis Drug Distributors List Table 119. Granulomatosis with Polyangiitis Drug Customers List Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Granulomatosis with Polyangiitis Drug Product Image Figure 2. Global Granulomatosis with Polyangiitis Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Granulomatosis with Polyangiitis Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Granulomatosis with Polyangiitis Drug Sales (2021-2032) & (W Units) Figure 5. Global Granulomatosis with Polyangiitis Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Granulomatosis with Polyangiitis Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Avacopan Image Figure 10. Benralizumab Image Figure 11. Rituximab Biosimilar Image Figure 12. Others Image Figure 13. Global Granulomatosis with Polyangiitis Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Granulomatosis with Polyangiitis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Granulomatosis with Polyangiitis Drug Sales Volume Share by Type (2021-2032) Figure 16. Global Granulomatosis with Polyangiitis Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Granulomatosis with Polyangiitis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Granulomatosis with Polyangiitis Drug Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Others Image Figure 22. Global Granulomatosis with Polyangiitis Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 23. Global Granulomatosis with Polyangiitis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Granulomatosis with Polyangiitis Drug Sales Volume Share by Application (2021-2032) Figure 25. Global Granulomatosis with Polyangiitis Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Granulomatosis with Polyangiitis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Granulomatosis with Polyangiitis Drug Sales Value Share by Application (2021-2032) Figure 28. Global Granulomatosis with Polyangiitis Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 29. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Granulomatosis with Polyangiitis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Granulomatosis with Polyangiitis Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Granulomatosis with Polyangiitis Drug Sales Value (2021-2032) & (US$ Million) Figure 33. North America Granulomatosis with Polyangiitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Granulomatosis with Polyangiitis Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Granulomatosis with Polyangiitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Granulomatosis with Polyangiitis Drug Sales Value (2021-2032) & (US$ Million) Figure 39. South America Granulomatosis with Polyangiitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Granulomatosis with Polyangiitis Drug Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Granulomatosis with Polyangiitis Drug Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Avacopan
  • Benralizumab
  • Rituximab Biosimilar
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Sandoz International GmbH
  • GlaxoSmithKline Plc
  • The International Biotechnology Center (IBC) Generium
  • Panacea Biotec Ltd
  • Iltoo Pharma
  • Genor BioPharma Co Ltd
  • Coherus BioSciences Inc
  • ChemoCentryx Inc
  • Bristol-Myers Squibb Company
  • Bionovis SA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Granulomatosis with Polyangiitis Drug Sales Value (2021-2032)
  4. 1.2.2 Global Granulomatosis with Polyangiitis Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Granulomatosis with Polyangiitis Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Granulomatosis with Polyangiitis Drug Market Dynamics
  1. 2.1 Granulomatosis with Polyangiitis Drug Industry Trends
  2. 2.2 Granulomatosis with Polyangiitis Drug Industry Drivers
  3. 2.3 Granulomatosis with Polyangiitis Drug Industry Opportunities and Challenges
  4. 2.4 Granulomatosis with Polyangiitis Drug Industry Restraints
3 Granulomatosis with Polyangiitis Drug Market by Company
  1. 3.1 Global Granulomatosis with Polyangiitis Drug Company Revenue Ranking in 2025
  2. 3.2 Global Granulomatosis with Polyangiitis Drug Revenue by Company (2021-2026)
  3. 3.3 Global Granulomatosis with Polyangiitis Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Granulomatosis with Polyangiitis Drug Average Price by Company (2021-2026)
  5. 3.5 Global Granulomatosis with Polyangiitis Drug Company Ranking (2024-2026)
  6. 3.6 Global Granulomatosis with Polyangiitis Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Granulomatosis with Polyangiitis Drug Company Product Type and Application
  8. 3.8 Global Granulomatosis with Polyangiitis Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Granulomatosis with Polyangiitis Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Granulomatosis with Polyangiitis Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Granulomatosis with Polyangiitis Drug Market by Type
  1. 4.1 Granulomatosis with Polyangiitis Drug Type Introduction
  2. 4.1.1 Avacopan
  3. 4.1.2 Benralizumab
  4. 4.1.3 Rituximab Biosimilar
  5. 4.1.4 Others
  6. 4.2 Global Granulomatosis with Polyangiitis Drug Sales Volume by Type
  7. 4.2.1 Global Granulomatosis with Polyangiitis Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Granulomatosis with Polyangiitis Drug Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Granulomatosis with Polyangiitis Drug Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Granulomatosis with Polyangiitis Drug Sales Value by Type
  11. 4.3.1 Global Granulomatosis with Polyangiitis Drug Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Granulomatosis with Polyangiitis Drug Sales Value by Type (2021-2032)
  13. 4.3.3 Global Granulomatosis with Polyangiitis Drug Sales Value Share by Type (2021-2032)
5 Granulomatosis with Polyangiitis Drug Market by Application
  1. 5.1 Granulomatosis with Polyangiitis Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Granulomatosis with Polyangiitis Drug Sales Volume by Application
  6. 5.2.1 Global Granulomatosis with Polyangiitis Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Granulomatosis with Polyangiitis Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Granulomatosis with Polyangiitis Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Granulomatosis with Polyangiitis Drug Sales Value by Application
  10. 5.3.1 Global Granulomatosis with Polyangiitis Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Granulomatosis with Polyangiitis Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Granulomatosis with Polyangiitis Drug Sales Value Share by Application (2021-2032)
6 Granulomatosis with Polyangiitis Drug Regional Sales and Value Analysis
  1. 6.1 Global Granulomatosis with Polyangiitis Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Granulomatosis with Polyangiitis Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Granulomatosis with Polyangiitis Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Granulomatosis with Polyangiitis Drug Sales by Region (2027-2032)
  5. 6.3 Global Granulomatosis with Polyangiitis Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Granulomatosis with Polyangiitis Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Granulomatosis with Polyangiitis Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Granulomatosis with Polyangiitis Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Granulomatosis with Polyangiitis Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Granulomatosis with Polyangiitis Drug Sales Value (2021-2032)
  12. 6.6.2 North America Granulomatosis with Polyangiitis Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Granulomatosis with Polyangiitis Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Granulomatosis with Polyangiitis Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Granulomatosis with Polyangiitis Drug Sales Value (2021-2032)
  21. 6.9.2 South America Granulomatosis with Polyangiitis Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Value Share by Country, 2025 VS 2032
7 Granulomatosis with Polyangiitis Drug Country-level Sales and Value Analysis
  1. 7.1 Global Granulomatosis with Polyangiitis Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Granulomatosis with Polyangiitis Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Granulomatosis with Polyangiitis Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Granulomatosis with Polyangiitis Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Granulomatosis with Polyangiitis Drug Sales by Country (2027-2032)
  6. 7.4 Global Granulomatosis with Polyangiitis Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Granulomatosis with Polyangiitis Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Granulomatosis with Polyangiitis Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Granulomatosis with Polyangiitis Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Granulomatosis with Polyangiitis Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Granulomatosis with Polyangiitis Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sandoz International GmbH
  2. 8.1.1 Sandoz International GmbH Company Information
  3. 8.1.2 Sandoz International GmbH Business Overview
  4. 8.1.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product Portfolio
  6. 8.1.5 Sandoz International GmbH Recent Developments
  7. 8.2 GlaxoSmithKline Plc
  8. 8.2.1 GlaxoSmithKline Plc Company Information
  9. 8.2.2 GlaxoSmithKline Plc Business Overview
  10. 8.2.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product Portfolio
  12. 8.2.5 GlaxoSmithKline Plc Recent Developments
  13. 8.3 The International Biotechnology Center (IBC) Generium
  14. 8.3.1 The International Biotechnology Center (IBC) Generium Company Information
  15. 8.3.2 The International Biotechnology Center (IBC) Generium Business Overview
  16. 8.3.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product Portfolio
  18. 8.3.5 The International Biotechnology Center (IBC) Generium Recent Developments
  19. 8.4 Panacea Biotec Ltd
  20. 8.4.1 Panacea Biotec Ltd Company Information
  21. 8.4.2 Panacea Biotec Ltd Business Overview
  22. 8.4.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product Portfolio
  24. 8.4.5 Panacea Biotec Ltd Recent Developments
  25. 8.5 Iltoo Pharma
  26. 8.5.1 Iltoo Pharma Company Information
  27. 8.5.2 Iltoo Pharma Business Overview
  28. 8.5.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Iltoo Pharma Granulomatosis with Polyangiitis Drug Product Portfolio
  30. 8.5.5 Iltoo Pharma Recent Developments
  31. 8.6 Genor BioPharma Co Ltd
  32. 8.6.1 Genor BioPharma Co Ltd Company Information
  33. 8.6.2 Genor BioPharma Co Ltd Business Overview
  34. 8.6.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product Portfolio
  36. 8.6.5 Genor BioPharma Co Ltd Recent Developments
  37. 8.7 Coherus BioSciences Inc
  38. 8.7.1 Coherus BioSciences Inc Company Information
  39. 8.7.2 Coherus BioSciences Inc Business Overview
  40. 8.7.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product Portfolio
  42. 8.7.5 Coherus BioSciences Inc Recent Developments
  43. 8.8 ChemoCentryx Inc
  44. 8.8.1 ChemoCentryx Inc Company Information
  45. 8.8.2 ChemoCentryx Inc Business Overview
  46. 8.8.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product Portfolio
  48. 8.8.5 ChemoCentryx Inc Recent Developments
  49. 8.9 Bristol-Myers Squibb Company
  50. 8.9.1 Bristol-Myers Squibb Company Company Information
  51. 8.9.2 Bristol-Myers Squibb Company Business Overview
  52. 8.9.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product Portfolio
  54. 8.9.5 Bristol-Myers Squibb Company Recent Developments
  55. 8.10 Bionovis SA
  56. 8.10.1 Bionovis SA Company Information
  57. 8.10.2 Bionovis SA Business Overview
  58. 8.10.3 Bionovis SA Granulomatosis with Polyangiitis Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Bionovis SA Granulomatosis with Polyangiitis Drug Product Portfolio
  60. 8.10.5 Bionovis SA Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Granulomatosis with Polyangiitis Drug Value Chain Analysis
  2. 9.1.1 Granulomatosis with Polyangiitis Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Granulomatosis with Polyangiitis Drug Sales Mode & Process
  6. 9.2 Granulomatosis with Polyangiitis Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Granulomatosis with Polyangiitis Drug Distributors
  9. 9.2.3 Granulomatosis with Polyangiitis Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst